Franklin Resources
APGE icon

Franklin Resources’s Apogee Therapeutics APGE Stock Holding History

Franklin Resources’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-363,379
Closed -$48.2M – 3178
2026
Q2 		$48.2M Sell
363,379
-42,159
-10% -$3.8M 0.01% 695
2026
Q1 		$34.1M Sell
405,538
-45,464
-10% -$3.3M 0.01% 772
2025
Q4 		$34M Sell
451,002
-279,759
-38% -$17.6M 0.01% 769
2025
Q3 		$29M Sell
730,761
-121,770
-14% -$4.65M 0.01% 833
2025
Q2 		$37M Sell
852,531
-23,545
-3% -$896K 0.01% 726
2025
Q1 		$32.7M Buy
876,076
+9,888
+1% +$382K 0.01% 739
2024
Q4 		$39.2M Buy
866,188
+5,199
+0.6% +$265K 0.01% 691
2024
Q3 		$48.1M Sell
860,989
-144,481
-14% -$6.92M 0.01% 618
2024
Q2 		$39.6M Sell
1,005,470
-29,910
-3% -$1.45M 0.01% 622
2024
Q1 		$68.8M Sell
1,035,380
-54,400
-5% -$2.38M 0.02% 472
2023
Q4 		$30.4M Buy
1,089,780
+92,423
+9% +$1.85M 0.01% 650
2023
Q3 		$21.2M Buy
+997,357
New +$22M 0.01% 725

Other funds holding APGE

IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Allworth Financial
Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

Franklin Resources's APGE Position: Q3 2026 in Review

Franklin Resources sold out of Apogee Therapeutics (APGE) in Q3 2026, closing a stake of 363,379 shares — an estimated $48.2M sold.

Franklin Resources first reported a position in APGE in Q3 2023 and held it in 12 quarters. The position peaked at $68.8M in Q1 2024. 2 funds tracked by Wall St. Rank hold APGE as of Q3 2026.

  • Franklin Resources reported no remaining Apogee Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Franklin Resources sold 363,379 Apogee Therapeutics shares in Q3 2026, an estimated $48.2M.
  • Franklin Resources first reported a position in Apogee Therapeutics in Q3 2023 and held it in 12 quarters.
  • Franklin Resources's Apogee Therapeutics position peaked at $68.8M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2026.

Based on Franklin Resources's 13F filing for Q3 2026, filed 12 Nov 2026.